LINC00572

 

Full name: long intergenic non-protein coding RNA 572 Alias Symbol: 
Type: non-coding RNA Cytoband: 13q12.3
Entrez ID: 100861573 HGNC ID: HGNC:43722 Ensembl Gene: ENSG00000224405 OMIM ID: 
Drug and gene relationship at DGIdb

 

Expression of LINC00572:

 

Dataset Gene EntrezID Probe Log2FC Adj.pValue Expression
GSE17351 LINC00572 100861573 1563296_at -0.2296 0.2385
GSE26886 LINC00572 100861573 1563296_at -0.0186 0.8550
GSE45670 LINC00572 100861573 1563296_at 0.0524 0.5702
GSE53622 LINC00572 100861573 73924 0.5659 0.0000
GSE53624 LINC00572 100861573 73924 0.6321 0.0000
GSE63941 LINC00572 100861573 1563296_at 0.0302 0.8524
GSE77861 LINC00572 100861573 1563296_at -0.1178 0.2060

Upregulated datasets: 0; Downregulated datasets: 0.  


 

Survival by LINC00572 expression:

 

GSE53622GSE53624

 

Note: Click image to view full size file.  


Copy number change of LINC00572:

 

Dataset Gene EntrezID Gain Loss Normal Detail
GSE15526 LINC00572 100861573 1 13 16
GSE20123 LINC00572 100861573 1 12 17
GSE43470 LINC00572 100861573 2 12 29
GSE46452 LINC00572 100861573 0 33 26
GSE47630 LINC00572 100861573 2 27 11
GSE54993 LINC00572 100861573 12 2 56
GSE54994 LINC00572 100861573 2 14 37
GSE60625 LINC00572 100861573 0 3 8
GSE74703 LINC00572 100861573 2 9 25
GSE74704 LINC00572 100861573 0 10 10
TCGA LINC00572 100861573 8 37 51

Total number of gains: 30; Total number of losses: 172; Total Number of normals: 286.  


 

Somatic mutations of LINC00572:

 

Generating mutation plots.

 

Highly correlated genes for LINC00572:

 

Showing all 14 correlated genes with mean PCC>0.5.

Gene1 Gene2 Mean PCC Num. Datasets Num. PCC<0 Num. PCC>0.5
LINC00572LINC011800.612559303
LINC00572LINC013660.599648403
LINC00572CNTFR-AS10.590523303
LINC00572TAS2R410.580944303
LINC00572CYP2A70.568348503
LINC00572ZNF6190.556114403
LINC00572CAMK2B0.545194403
LINC00572CARS-AS10.534594403
LINC00572GPR500.523413503
LINC00572LYPD80.519293403
LINC00572TMEM1050.517458403
LINC00572TNFRSF13C0.513459503
LINC00572NR1I30.51269403
LINC00572CCR40.501204403

For details and further investigation, click here